Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 18/20 | 0.76 |
| ▸ | AKR1C1 | Q04828 | 5/20 | 0.74 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.71 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3280649 | 0.95 | AKR1C3 (0.76) | AKR1C3AKR1C1ESR2MEN1KMT2A | |
| SCHEMBL17786050 | 0.88 | AKR1C3 (0.73) | AKR1C3AKR1C1ESR2 | |
| SCHEMBL1264112 | 0.87 | HDAC6 (0.74) | AKR1C3AKR1C1ESR2MEN1KMT2A | |
| SCHEMBL3286988 | 0.87 | AKR1C3 (0.73) | AKR1C3AKR1C1MEN1KMT2A | |
| SCHEMBL7868653 | 0.86 | ESR2 (0.64) | AKR1C3AKR1C1ESR2MEN1KMT2A | |
| SCHEMBL30819658 | 0.85 | AKR1C3 (1.00) | AKR1C3AKR1C1MEN1KMT2AALDH1A1 | |
| SCHEMBL2011206 | 0.85 | AKR1C3 (1.00) | AKR1C3AKR1C1MEN1KMT2AALDH1A1 | |
| SCHEMBL17786044 | 0.85 | AKR1C3 (0.62) | AKR1C3AKR1C1ESR2 | |
| SCHEMBL4012085 | 0.83 | AKR1C3 (0.73) | AKR1C3AKR1C1MEN1KMT2A | |
| SCHEMBL3282044 | 0.83 | AKR1C3 (0.73) | AKR1C3AKR1C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10829453-B2 | Antagonists of the kappa opioid receptor | UNIVERSITY OF KANSAS (US) | 2020-11-10 | — | — | US | disclosed |
| US-20190300486-A1 | ANTAGONISTS OF THE KAPPA OPIOID RECEPTOR | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2019-10-03 | — | — | US | disclosed |
| US-20170260141-A1 | ANTAGONISTS OF THE KAPPA OPIOID RECEPTOR | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2017-09-14 | — | — | US | disclosed |
| US-20170260141-A1 | ANTAGONISTS OF THE KAPPA OPIOID RECEPTOR | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2017-09-14 | — | — | US | disclosed |
| US-8946259-B2 | Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors | HIGH POINT PHARMACEUTICALS, LLC (US) | 2015-02-03 | — | — | US | disclosed |
| US-20140066477-A1 | Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors | HIGH POINT PHARMACEUTICALS, LLC (US) | 2014-03-06 | — | — | US | disclosed |
| US-8598353-B2 | Benzazole derivatives, compositions, and methods of use as β-secretase inhibitors | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-12-03 | — | — | US | disclosed |
| EP-1863771-B1 | BENZAZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE AS B-SECRETASE INHIBITORS | HIGH POINT PHARMACEUTICALS LLC (US) | 2012-11-07 | — | — | EP | disclosed |
| EP-2457901-A1 | Benzazole derivatives, compositions, and methods of use as B-secretase inhibitors | High Point Pharmaceuticals, LLC (US) | 2012-05-30 | — | — | EP | disclosed |
| US-20090326006-A1 | Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors | VTVX HOLDINGS II LLC | 2009-12-31 | — | — | US | disclosed |
| EP-1863771-A2 | BENZAZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE AS B-SECRETASE INHIBITORS | Transtech Pharma, Inc. (US) | 2007-12-12 | — | — | EP | disclosed |
| US-20060223849-A1 | Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors | HIGH POINT PHARMACEUTICALS, LLC | 2006-10-05 | — | — | US | disclosed |
| WO-2006099379-A2 | BENZAZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE AS B-SECRETASE INHIBITORS | TRANSTECH PHARMA, INC. (US) | 2006-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326006-A1 | Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors | BACE1, BACE2, APP | AKR1C3 1601/4885AKR1C1 1984/4885ESR2 2081/4885 |
| US-10829453-B2 | Antagonists of the kappa opioid receptor | OPRK1, OPRD1, OPRL1 | AKR1C3 3195/4885AKR1C1 3241/4885ESR2 1297/4885 |
| US-20060223849-A1 | Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors | BACE1, BACE2, APP | AKR1C3 1601/4885AKR1C1 1984/4885ESR2 2081/4885 |
| US-20190300486-A1 | ANTAGONISTS OF THE KAPPA OPIOID RECEPTOR | OPRK1, OPRD1, OPRL1 | AKR1C3 3195/4885AKR1C1 3241/4885ESR2 1297/4885 |
| US-20170260141-A1 | ANTAGONISTS OF THE KAPPA OPIOID RECEPTOR | OPRK1, OPRD1, OPRL1 | AKR1C3 3195/4885AKR1C1 3241/4885ESR2 1297/4885 |
| US-20140066477-A1 | Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors | BACE1, BACE2, APP | AKR1C3 1601/4885AKR1C1 1984/4885ESR2 2081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.